Community-led monitoring of opioid agonist treatment including WHO quality of life indicators.
Community-led monitoring of opioid agonist treatment including WHO quality of life indicators.
The CLM initiative led to policy changes in Ukraine, Georgia, Montenegro, and Moldova. For instance, in Ukraine, the research revealed gaps in psychological and social support within the OAT programme, prompting advocacy efforts to address these deficiencies. In Georgia, the findings influenced decisions on take-home dosing, while in Moldova, they sparked a formal investigation into programme outcomes. Additionally, the research led to increased access to buprenorphine in Moldova and improved staffing at a central clinic in Montenegro. (EHRA - Eurasian Harm Reduction Association, Wilna/Litauen, 2024)
https://ehra-uploads.s3.eu-central-1.amazonaws.com/d2768551-48e0-4ecb-a6e3-b2b282496bd8.pdf